Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant

Journal of Cellular Biochemistry

Volumn 98, Issue 5, 2006, Pages 1037-1043

  Loukinov, Dmitri ^a   Ghochikyan, Anahit ^b   Mkrtichyan, Mikayel ^b   Ichim, Thomas E ^c   Lobanenkov, Victor V ^a   Cribbs, David H ^d   Agadjanyan, Michael C ^b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^c Oncomune   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BORIS; Breast cancer; CT antigens; Mammary tumor; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CANCER TESTIS ANTIGEN; DNA BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; TRANSCRIPTION FACTOR BORIS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BORIS GENE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFICACY; ENERGY; EPIGENETICS; EXPRESSION VECTOR; FEMALE; GENE; GENE GUN; GENE REPRESSION; GENOME IMPRINTING; IMMUNOGENICITY; MAGE A1 GENE; MOUSE; MOUSE STRAIN; NONHUMAN; NY ESO 1 GENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; SURVIVAL TIME; TISSUE SPECIFICITY; VACCINATION; X CHROMOSOME INACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CELL LINE, TUMOR; CRICETINAE; DNA; DNA-BINDING PROTEINS; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; SURVIVAL RATE; VACCINATION;

MURINAE;

EID: 33746421457     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20953     Document Type: Article

References (31)

1. Browning M, Dunnion D. 1997. HLA and cancer: Implications for cancer immunotherapy and vaccination. Eur J Immunogenet 24:293-312.
2. Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, Maraskovsky E, Green S, Miloradovic L, McCluskey J, Old LJ, Davis ID, Cebon J, Chen W. 2004. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 101:9363-9368.
3. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. 2004. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64:2205-2211.
4. Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Ichim T, Lobanenkov W, Cribbs DH, Agadjanyan MG. 2006. The epigenetically acting tumor promoting transcription factor BORIS is a widely expressed tumor-associated antigen recognized by CD8+ cytotoxic lymphocytes (submitted).
5. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov W, Schrump DS. 2005. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65:7763-7774.
6. Ikeda H. 2003. Clinical trials targeting advanced cancers by active immunization of T-cell defined tumor antigens. Curr Pharm Des 9:1133-1138.
7. Iwasaki A, Steirnholm BJN, Chan AK, Breinstein NL, Barber BH. 1997. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158:4591-4601.
8. Kim JJ, Bagarazzi M, Hu Y, Traverdi N, Chattergoon M, Dang K, Mahalingam S, Boyer J, Agadjanyan MG, Weiner DB. 1997. Engineering of in vivo immune responses to DNA immunization via co-delivery of costimulatory molecule genes. Nature Biotech 15:641-646.
9. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. 2003. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9:3222-3234.
10. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. 2003. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63:1860-1864.
11. Le Poole IC, Bommiasamy H, Kast WM. 2003. Recent progress in tumour vaccine development. Expert Opin Investig Drugs 12:971-981.
12. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC III, Lobanenkov W. 2002. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 99: 6806-6811.
13. Miller FR, Miller BE, Heppner GH. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: Heterogeneity in pheno-typic stability. Invasion Metastasis 3:22-31.
14. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166-6173.
15. Mitsuhashi M, Liu J, Cao S, Shi X, Ma X. 2004. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76:322-332.
16. Miura T, Mizuki D, Sasaki S, Hasegawa S, Sashinami H, Nakane A. 2000. Host resistance to Listeria monocytogenes infection is enhanced but resistance to Staphylococcus aureus infection is reduced in acute graft-versus-host disease in mice. Infect Immun 68:4340-4343.
17. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551-1559.
18. Pulaski BA, Ostrand-Rosenberg S. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486-1493.
19. Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10: 909-915.
20. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. 2002. Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32.
21. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. 2005. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625.
22. Smyth MJ, Godfrey DI, Trapani JA. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293-299.
23. Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, Kawamoto S, Sasaki S, Matsunaga K, Ishigatsubo Y, Tani K, Okubo T, Okuda K. 1997. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 27:782-787.
24. Van den Eynde B, Van der Bruggen P. 2004. T-cell defined tumor antigens http://www.cancerimmunity.org/ peptidedatabase/Tcellepitopes.htm.
25. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
26. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229-250.
27. Vasilevko V, Ghochikyan A, Sadzikava N, Petrushina I, Tran M, Cohen EP, Kesslak PJ, Cribbs DH, Nicolson GL, Agadjanyan MG. 2003. Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors. Clin Exp Metastasis 20:489-498.
28. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H III, Schrump DS, Risinger JI, Barrett JC, Lobanenkov W. 2005. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65: 7751-7762.
29. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679.
30. Wang H, Hosiawa KA, Min W, Yang J, Zhang X, Garcia B, Ichim TE, Zhou D, Lian D, Kelvin DJ, Zhong R. 2003. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol 171: 3823-3836.
31. Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, McEarchern JA, Akporiaye ET. 2001. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 50:229-240.